Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with P-MAPA and systemic administration of cisplatin and doxorubicin

Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with P-MAPA and systemic administration of cisplatin and doxorubicin

ABSTRACT The present study describes the histopathological and molecular effects of P-MAPA (Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride) intravesical immunotherapy combined with systemic doxorubicin or cisplatin for treatment of non-muscle invasive bladder cancer (NM...

Full description

Bibliographic Details
Main Authors:	Queila Cristina Dias, Iseu da Silva Nunes, Patrick Vianna Garcia, Wagner José Fávaro
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia
Series:	International Brazilian Journal of Urology
Subjects:	Urinary Bladder Neoplasms Immunotherapy Cisplatin Doxorubicin
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000500942&lng=en&tlng=en

Similar Items

The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection
by: Musa I Al-Gallab, et al.
Published: (2009-04-01)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
by: Jan-Friedrich Jokisch, et al.
Published: (2015-01-01)

Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin in treating bladder cancer
by: Dah-Shyong Yu, et al.
Published: (2017-12-01)

Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin
by: Milošević Radovan, et al.
Published: (2015-01-01)

17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer
by: C. W. Cheng, et al.
Published: (2005-06-01)

Time-dependent simvastatin administration enhances doxorubicin toxicity in neuroblastoma
by: Colin C. Anderson, et al.
Published: (2020-01-01)

Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines
by: Sung Han Kim, et al.
Published: (2016-01-01)

Sulforaphane Potentiates Anticancer Effects of Doxorubicin and Cisplatin and Mitigates Their Toxic Effects
by: Cinzia Calcabrini, et al.
Published: (2020-05-01)

COMPARATIVE ANALYSIS OF THE THERAPEUTIC EFFICACY OF PROSPIDINE AND CISPLATIN IN NEOADJUVANT INTRAVESICAL CHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: T. I. Shabunina, et al.
Published: (2014-07-01)

COMPARATIVE ANALYSIS OF THE THERAPEUTIC EFFICACY OF PROSPIDINE AND CISPLATIN IN NEOADJUVANT INTRAVESICAL CHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: T. I. Shabunina, et al.
Published: (2014-07-01)

Hypoxia potentiates the capacity of melanoma cells to evade cisplatin and doxorubicin cytotoxicity via glycolytic shift
by: Ming Zhuo, et al.
Published: (2020-05-01)

Intravesical wire as foreign body in urinary bladder
by: Dilip K. Pal, et al.
Published: (2005-10-01)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
by: Bin Zhang, et al.
Published: (2020-02-01)

INTRAVESICAL THERAPY FOR BLADDER CANCER: STATE-OF-THE ART
by: V. V. Protoshchak, et al.
Published: (2014-08-01)

INTRAVESICAL THERAPY FOR BLADDER CANCER: STATE-OF-THE ART
by: V. V. Protoshchak, et al.
Published: (2014-08-01)

Intravesical electrical stimulation treatment for overactive bladder: An observational study
by: J. Joshua Yune, et al.
Published: (2018-07-01)

Arteriovenous Hemangioma of the Urinary Bladder Following Intravesical Treatment
by: Ali Sarıbacak, et al.
Published: (2011-09-01)

Study Protocol: Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Metastases
by: Manuela Robella, et al.
Published: (2021-05-01)

L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells
by: Agustina DR Nurcahyanti, et al.
Published: (2016-01-01)

P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling
by: Luiz Gustavo de Almeida Chuffa, et al.
Published: (2018-01-01)

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report
by: Clemens B. Tempfer, et al.
Published: (2014-12-01)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
by: Tatiana V. Gorodnova, et al.
Published: (2021-02-01)

Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
by: Daniel Herchenhorn, et al.
Published: (2007-10-01)

Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
by: Doo Yong Chung, et al.
Published: (2021-06-01)

What have we learned after 30 years of BCG intravesical therapy for superficial bladder cancer?
by: Marcos Tobias-Machado, et al.
Published: (2009-12-01)

Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result
by: Lokman Irkilata, et al.
Published: (2015-06-01)

Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
by: Gry A. Taarnhøj, et al.
Published: (2020-05-01)

Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies
by: Jin X, et al.
Published: (2016-09-01)

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies
by: Makito Miyake, et al.
Published: (2021-05-01)

Bacillary Prostatitis after Intravesical Immunotherapy:A Rare Adverse Effect
by: Ana Joaquim, et al.
Published: (2012-02-01)

Effect of rutin on oxidative and proinflammatory damage induced by cisplatin in blood serum, ureter, bladder and urethra in rats
by: Hirik Erkan, et al.
Published: (2020-01-01)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
by: Ashish M. Kamat, et al.
Published: (2017-08-01)

Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
by: Mikołaj Wołącewicz, et al.
Published: (2020-05-01)

Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity
by: Lijie Wen, et al.
Published: (2020-04-01)

Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells
by: Lin JF, et al.
Published: (2017-05-01)

Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
by: Daher C. Chade, et al.
Published: (2009-12-01)

The clinical course of non-muscle invasive bladder cancer after transuretral resection of the tumor with or without subsequent intravesical application of bacillus Calmette-Guérin: The influence of patients gender and age
by: Milošević Radovan, et al.
Published: (2015-01-01)

Overactive bladder syndrome and bladder wall thickness in patients with obstructive sleep apnea syndrome
by: Zahide Yilmaz, et al.

Oxytocin Reduces Intravesical Pressure in Anesthetized Female Rats: Action on Oxytocin Receptors of the Urinary Bladder
by: Eduardo M. Cafarchio, et al.
Published: (2020-05-01)

Can intravesical prostatic protrusion predict bladder outlet obstruction even in men with good flow?
by: Alvin Lee, et al.
Published: (2016-01-01)